EQL — EQL Pharma AB Cashflow Statement
0.000.00%
- SEK2.30bn
- SEK2.44bn
- SEK264.17m
Annual cashflow statement for EQL Pharma AB, fiscal year end - March 31st, SEK millions except per share, conversion factor applied.
2020 March 31st | C2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 2.72 | 10.4 | 36 | 39 | 32.6 |
Depreciation | |||||
Non-Cash Items | 0 | 18.4 | 13 | 14.2 | -5.83 |
Other Non-Cash Items | |||||
Changes in Working Capital | -0.171 | 31.3 | -7.18 | -25.5 | -47 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 6.69 | 60 | 41.8 | 27.6 | -11.4 |
Capital Expenditures | -17.6 | -55.6 | -22.1 | -20.5 | -66.3 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -0.479 | — | — | -0.001 | — |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -18.1 | -55.6 | -22.1 | -20.5 | -66.3 |
Financing Cash Flow Items | 0.006 | — | — | 0.001 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.006 | 11.8 | -5.12 | -3.88 | 53.7 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -11.4 | 16.3 | 14.6 | 3.23 | -24 |